Patel Monika, Gandhi Rohankumar, Satapara Niketkumar, Babaria Dhruvam L, Vala Rishita Bakulbhai, Murugan Yogesh
Community and Family Medicine, Guru Gobind Singh Government Hospital, Jamnagar, IND.
Community and Family Medicine, Shri M.P. Shah Medical college, Jamnagar, IND.
Cureus. 2024 Apr 27;16(4):e59177. doi: 10.7759/cureus.59177. eCollection 2024 Apr.
The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has had far-reaching implications beyond the respiratory system. Mounting evidence suggests that COVID-19 can impact various organ systems, including the eyes. This study aimed to elucidate the prevalence, characteristics, and clinical implications of ophthalmic manifestations in patients diagnosed with COVID-19.
This retrospective study analyzed data from electronic medical records of adult patients hospitalized with COVID-19 between March 1, 2020, and December 31, 2020, at a large tertiary academic medical center. Ophthalmic manifestations, including conjunctivitis, dry eye symptoms, ocular pain, epiphora, ocular redness, and visual disturbances, were identified and examined for their prevalence, onset, duration, and associations with COVID-19 severity and systemic symptoms.
Among 342 patients included in the study, 106 (31.0%) experienced at least one ophthalmic manifestation during their COVID-19 illness. Conjunctivitis was the most common manifestation in 62 patients (18.1%), followed by dry eye symptoms in 38 patients (11.1%), ocular pain/discomfort in 27 patients (7.9%), epiphora in 19 patients (5.6%), ocular redness in 14 patients (4.1%), and visual disturbances in nine patients (2.6%). Ophthalmic manifestations were significantly associated with severe COVID-19 illness (42.9% vs. 26.7%, p = 0.003) and the presence of systemic symptoms such as fever, cough, and dyspnea. The median time of onset was six days, and the median duration was 10 days.
Ophthalmic manifestations are prevalent in COVID-19 patients, particularly in those with severe illness and systemic symptoms. The study highlights the importance of recognizing and managing ocular symptoms in affected individuals and underscores the multifaceted nature of COVID-19, necessitating interdisciplinary collaboration for comprehensive patient care.
由严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)引起的2019冠状病毒病(COVID-19)大流行,其影响已远远超出呼吸系统。越来越多的证据表明,COVID-19可影响包括眼睛在内的多个器官系统。本研究旨在阐明COVID-19确诊患者眼部表现的患病率、特征及临床意义。
这项回顾性研究分析了2020年3月1日至2020年12月31日期间,在一家大型三级学术医疗中心因COVID-19住院的成年患者电子病历数据。识别眼部表现,包括结膜炎、干眼症状、眼痛、流泪、眼红和视觉障碍,并检查其患病率、发病时间、持续时间以及与COVID-19严重程度和全身症状的关联。
在纳入研究的342例患者中,106例(31.0%)在COVID-19患病期间出现至少一种眼部表现。结膜炎是最常见的表现,有62例患者(18.1%),其次是干眼症状38例(11.1%)、眼痛/不适27例(7.9%)、流泪19例(5.6%)、眼红14例(4.1%)和视觉障碍9例(2.6%)。眼部表现与严重COVID-19疾病(42.9%对26.7%,p = 0.003)以及发热、咳嗽和呼吸困难等全身症状显著相关。发病的中位时间为6天,中位持续时间为10天。
眼部表现在COVID-19患者中很常见,尤其是在病情严重和有全身症状的患者中。该研究强调了识别和处理受影响个体眼部症状的重要性,并强调了COVID-19的多方面性质,需要跨学科合作以提供全面的患者护理。